Doxofylline (also known as doxophylline) is a phosphodiesterase inhibiting bronchodilator used in the treatment of chronic respiratory diseases such as asthma [1] and COPD. [2] Like theophylline , it is a xanthine derivative.

Doxofylline is a methylxanthine derivative used in chronic obstructive pulmonary disease, asthma, and bronchospasms.

2021年9月28日 · Doxofylline is a bronchodilator, that helps relax the smooth muscles of the airways in your lungs. This medicine is available on prescription as a tablet, suspension, syrup and injection forms. Doxofylline may show some side effects like vomiting, headache, nausea, and an upset stomach.

2024年12月5日 · Doxofylline inhibits an enzyme called phosphodiesterase which results in bronchodilation (dilation or widening of the airways in the lungs by relaxing the surrounding smooth muscle). It is used for the treatment of asthma and …

Explore Doxofylline, a bronchodilator used for asthma and COPD management. Learn about its dosage, side effects, and precautions.

2022年12月23日 · Doxofylline has been found to be approved for relieving symptoms and for the treatment and maintenance of episodes of chronic asthma, chronic bronchitis, and Chronic Obstructive Pulmonary Disease. Doxofylline is absorbed with an …

2024年11月8日 · Discover comprehensive details about Doxofylline, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. …

Doxofylline is a newer generation xanthine with both bronchodilating and anti-inflammatory activities and for this reason it has been called “novofylline”. It differs substantially from theophylline at the pharmacological level.

Each tablet contains 200 mg Doxofylline. For the treatment of COPD, bronchial asthma and pulmonary disease with spastic bronchial component. Elderly Patients: 200 mg tablet two or three times daily. Adults: 400 mg tablet two or three times daily or as prescribed by a physician.

Doxofylline is a methylxanthine bronchodilator with potent bronchodilator activity comparable to that of theophylline. In animal studies, doxofylline demonstrated to attenuate bronchoconstriction, inflammatory actions and the release of thromboxane A2 when challenged with platelet-activating factor. Doxofylline does not demonstrate direct ...